[{"id":"c40dc4d0-3098-4b80-a43d-a8ca31016907","acronym":"GREKO III","url":"https://clinicaltrials.gov/study/NCT03464201","created_at":"2021-04-19T04:53:15.041Z","updated_at":"2025-02-25T15:34:04.428Z","phase":"Phase 2","brief_title":"Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study","source_id_and_acronym":"NCT03464201 - GREKO III","lead_sponsor":"Grupo Español de Tumores Huérfanos e Infrecuentes","biomarkers":" FOXL2","pipe":"","alterations":" ","tags":["FOXL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 04/13/2018","start_date":" 04/13/2018","primary_txt":" Primary completion: 11/11/2020","primary_completion_date":" 11/11/2020","study_txt":" Completion: 11/11/2020","study_completion_date":" 11/11/2020","last_update_posted":"2023-02-22"}]